open access

Vol 70, No 5 (2019)
Original Paper
Published online: 2019-06-12
Submitted: 2019-02-05
Accepted: 2019-06-02
Get Citation

Amiodarone-induced thyroid dysfunction in the developmental period: prenatally, in childhood, and adolescence — case reports and a review of the literature

Aleksandra Furtak, Anna Wędrychowicz, Anna Kalicka-Kasperczyk, Dominika Januś, Małgorzata Wójcik, Zbigniew Kordon, Andrzej Rudziński, Jerzy B. Starzyk
DOI: 10.5603/EP.a2019.0030
·
Pubmed: 31274186
·
Endokrynologia Polska 2019;70(5):392-400.

open access

Vol 70, No 5 (2019)
Original Paper
Published online: 2019-06-12
Submitted: 2019-02-05
Accepted: 2019-06-02

Abstract

Introduction: Amiodarone is an important antiarrhythmic drug used in paediatric practice, mainly in children with complex congenital cardiac diseases and/or severe arrhythmias. One of the side effects of amiodarone therapy is thyroid dysfunction, which is observed in about 20% of patients. The thyroid dysfunction may present with various forms: from subclinical changes in hormone levels to amiodaroneinduced thyrotoxicosis (AIT) and amiodarone-induced hypothyroidism (AIH).

Material and methods: We reported six patients in the age range from two weeks to 14 years, with complex congenital cardiac diseases and severe arrhythmias, who developed amiodarone-induced thyroid dysfunctions: thyrotoxicosis or hypothyroidism or both together. The clinical signs and symptoms of all thyroid dysfunctions were atypical, most patients presented with an aggravation of heart insufficiency. Our patients with thyrotoxicosis were treated with combined therapy including thionamides and corticosteroids due to the presentation of mixed-identified type of AIT.

Results: Currently, five patients (one patient’s status is unknown) are in biochemical and clinical euthyreosis; however, in one of them it was impossible to discharge amiodarone treatment. Three of them are still treated with levothyroxine, and two do not need thyroid treatment.

Conclusions: Amiodarone-induced thyroid dysfunction is usually atypical; therefore, monitoring of thyroid status before, during, and after amiodarone is demanded. AIH could significantly influence the development of the child, while AIT could significantly deteriorate the clinical status of children with complex cardiac diseases. Early and proper diagnose of AIT and AIH allows the introduction of immediate and appropriate treatment considering the cardiac condition of the young patient.

Abstract

Introduction: Amiodarone is an important antiarrhythmic drug used in paediatric practice, mainly in children with complex congenital cardiac diseases and/or severe arrhythmias. One of the side effects of amiodarone therapy is thyroid dysfunction, which is observed in about 20% of patients. The thyroid dysfunction may present with various forms: from subclinical changes in hormone levels to amiodaroneinduced thyrotoxicosis (AIT) and amiodarone-induced hypothyroidism (AIH).

Material and methods: We reported six patients in the age range from two weeks to 14 years, with complex congenital cardiac diseases and severe arrhythmias, who developed amiodarone-induced thyroid dysfunctions: thyrotoxicosis or hypothyroidism or both together. The clinical signs and symptoms of all thyroid dysfunctions were atypical, most patients presented with an aggravation of heart insufficiency. Our patients with thyrotoxicosis were treated with combined therapy including thionamides and corticosteroids due to the presentation of mixed-identified type of AIT.

Results: Currently, five patients (one patient’s status is unknown) are in biochemical and clinical euthyreosis; however, in one of them it was impossible to discharge amiodarone treatment. Three of them are still treated with levothyroxine, and two do not need thyroid treatment.

Conclusions: Amiodarone-induced thyroid dysfunction is usually atypical; therefore, monitoring of thyroid status before, during, and after amiodarone is demanded. AIH could significantly influence the development of the child, while AIT could significantly deteriorate the clinical status of children with complex cardiac diseases. Early and proper diagnose of AIT and AIH allows the introduction of immediate and appropriate treatment considering the cardiac condition of the young patient.

Get Citation

Keywords

amiodarone; thyrotoxicosis; hypothyroidism; congenital heart disease

About this article
Title

Amiodarone-induced thyroid dysfunction in the developmental period: prenatally, in childhood, and adolescence — case reports and a review of the literature

Journal

Endokrynologia Polska

Issue

Vol 70, No 5 (2019)

Pages

392-400

Published online

2019-06-12

DOI

10.5603/EP.a2019.0030

Pubmed

31274186

Bibliographic record

Endokrynologia Polska 2019;70(5):392-400.

Keywords

amiodarone
thyrotoxicosis
hypothyroidism
congenital heart disease

Authors

Aleksandra Furtak
Anna Wędrychowicz
Anna Kalicka-Kasperczyk
Dominika Januś
Małgorzata Wójcik
Zbigniew Kordon
Andrzej Rudziński
Jerzy B. Starzyk

References (23)
  1. Bednarek-Tupikowska G, Filus A, Kuliczkowska J, et al. [Amiodarone and the thyroid gland]. Postepy Hig Med Dosw (Online). 2004; 58: 216–225.
  2. Martino E, Bartalena L, Bogazzi F, et al. The effects of amiodarone on the thyroid. Endocr Rev. 2001; 22(2): 240–254.
  3. Bogazzi F, Bartalena L, Martino E. Approach to the patient with amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab. 2010; 95(6): 2529–2535.
  4. Jastrzebska H. Effects of amiodarone on the thyroid function. Postepy Nauk Medycznych. 2012; 11: 882–887.
  5. Mroziński B, Bobkowski W, Siwińska A. Evaluation of influence on thyroid function of long-term therapy with amiodaron for supraventricular tachycardia in population of newborns and infants — own experience. Przegl Pediatr. 2006; 36: 119–123.
  6. Bossowski A. Nadczynność tarczycy u dzieci. Przyczyny, diagnostyka, objawy kliniczne i leczenie. In: Bossowski A. ed. Tyreologia wieku rozwojowego. Medical Tribune Polska, Warszawa 2013: 95–117.
  7. Hen K, Czarnywojtek A, Stangierski A, et al. [Effect of amiodarone on the thyroid function and safety of the therapy--what's new]. Przegl Lek. 2012; 69(10): 1135–1139.
  8. Hacihamdioğlu B, Berberoğlu M, Siklar Z, et al. Amiodarone-induced thyrotoxicosis in children and adolescents is a possible outcome in patients with low iodine intake. J Pediatr Endocrinol Metab. 2010; 23(4): 363–368.
  9. Kolesińska Z, Siuda K, Bobkowski W, et al. Amiodarone-induced thyrotoxicosis with paroxysmal supraventricular (ectopic atrial) tachycardia: case report and review of the literature. Arch Med Sci. 2013; 9(2): 372–376.
  10. Bartalena L, Bogazzi F, Braverman LE, et al. Effects of amiodarone administration during pregnancy on neonatal thyroid function and subsequent neurodevelopment. J Endocrinol Invest. 2001; 24(2): 116–130.
  11. Lomenick JP, Jackson WA, Backeljauw PF. Amiodarone-induced neonatal hypothyroidism: a unique form of transient early-onset hypothyroidism. J Perinatol. 2004; 24(6): 397–399.
  12. Kucharska AM, Beń-Skowronek I, Walczak M, et al. Congenital hypothyroidism — Polish recommendations for therapy, treatment monitoring, and screening tests in special categories of neonates with increased risk of hypothyroidism. Endokrynol Pol. 2016; 67(5): 536–547.
  13. Kanike N, Davis A, Shekhawat PS. Transient hypothyroidism in the newborn: to treat or not to treat. Transl Pediatr. 2017; 6(4): 349–358.
  14. Bartalena L, Bogazzi F, Chiovato L, et al. 2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction. Eur Thyroid J. 2018; 7(2): 55–66.
  15. Cohen-Lehman J, Dahl P, Danzi S, et al. Effects of amiodarone therapy on thyroid function. Nat Rev Endocrinol. 2010; 6(1): 34–41.
  16. Siuda K, Kolesińska Z, Niedziela M. [Amiodarone and thyroid function]. Kardiol Pol. 2011; 69(5): 493–498.
  17. Ben-Skowronek I, Jaklinska T, Szewczyk L. Skuteczne leczenie nadczynności tarczycy wywołanej amiodaronem u chłopca po wieloetapowej operacji kardiochirurgicznej. Endokrynol Ped. 2003; 2(Suppl).
  18. Czarnywojtek A, Warmuz-Stangierska I, Woliński K, et al. Radioiodine therapy in patients with type II amiodarone-induced thyrotoxicosis. Pol Arch Med Wewn. 2014; 124(12): 695–703.
  19. Krysiak R, Kowalcze K, Okopień B. [Rarer causes of thyrotoxicosis]. Przegl Lek. 2016; 73(4): 250–261.
  20. Ursella S, Testa A, Mazzone M, et al. Amiodarone-induced thyroid dysfunction in clinical practice. Eur Rev Med Pharmacol Sci. 2006; 10(5): 269–278.
  21. Czarnywojtek A, Płazińska MT, Zgorzalewicz-Stachowiak M, et al. Dysfunction of the thyroid gland during amiodarone therapy: a study of 297 cases. Ther Clin Risk Manag. 2016; 12: 505–513.
  22. Mateo Gavira I, Vilchez López F, Larrán Escandón L, et al. [Management of severe amiodarone-induced thyrotoxicosis after failure of standard medical treatment]. Endocrinol Nutr. 2013; 60(10): e43–e45.
  23. Flader M, Niedziela M. Radioiodine (I131) in the Treatment of Hyperthyroidism in Children. Endokrynol Ped. 2011; 34: 61–66.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl